Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03016819
Title A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma (APROMISS)
Acronym APROMISS
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Advenchen Laboratories, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | GBR | ESP


No variant requirements are available.